JP2007504235A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504235A5
JP2007504235A5 JP2006525396A JP2006525396A JP2007504235A5 JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5 JP 2006525396 A JP2006525396 A JP 2006525396A JP 2006525396 A JP2006525396 A JP 2006525396A JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heteroarylalkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525396A
Other languages
English (en)
Japanese (ja)
Other versions
JP4842817B2 (ja
JP2007504235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028308 external-priority patent/WO2005023815A2/en
Publication of JP2007504235A publication Critical patent/JP2007504235A/ja
Publication of JP2007504235A5 publication Critical patent/JP2007504235A5/ja
Application granted granted Critical
Publication of JP4842817B2 publication Critical patent/JP4842817B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006525396A 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法 Expired - Lifetime JP4842817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
US60/499,956 2003-09-03
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (3)

Publication Number Publication Date
JP2007504235A JP2007504235A (ja) 2007-03-01
JP2007504235A5 true JP2007504235A5 (enExample) 2007-10-04
JP4842817B2 JP4842817B2 (ja) 2011-12-21

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525396A Expired - Lifetime JP4842817B2 (ja) 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法

Country Status (9)

Country Link
US (2) US8067425B2 (enExample)
EP (1) EP1664050B1 (enExample)
JP (1) JP4842817B2 (enExample)
DK (1) DK1664050T3 (enExample)
ES (1) ES2564803T3 (enExample)
HU (1) HUE028528T2 (enExample)
PL (1) PL1664050T3 (enExample)
SI (1) SI1664050T1 (enExample)
WO (1) WO2005023815A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001279313B2 (en) 2000-08-04 2007-03-01 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
CA3050734A1 (en) 2003-05-15 2004-12-02 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8791117B2 (en) 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
WO2011037644A1 (en) * 2009-09-25 2011-03-31 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EA027343B1 (ru) 2011-10-10 2017-07-31 Ампио Фармасьютикалз, Инк. Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
CN104870452B (zh) * 2012-10-22 2018-04-13 希望之城 Etp衍生物
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
JP6574769B2 (ja) * 2013-07-25 2019-09-11 ニューレン ファーマシューティカルズ リミテッド 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US20190201395A1 (en) * 2016-05-26 2019-07-04 Amino Up Chemical Co., Ltd. Sleep improving agent
JP7088912B2 (ja) 2016-09-15 2022-06-21 シティ・オブ・ホープ ジチオetp誘導体
EP4663182A2 (en) 2018-03-16 2025-12-17 Scent Science International Inc. Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent
BR112020023252A2 (pt) * 2018-05-15 2021-02-23 Lloyd Hung Loi Tran composição do agente terapêutico e método de uso para tratamento de deficiência cognitiva leve, depressão e distúrbios psicológicos.
US12472177B2 (en) 2019-10-22 2025-11-18 Neuren Pharmaceuticals Limited Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome
IL305132A (en) * 2021-02-12 2023-10-01 Neuren Pharmaceuticals Ltd Preparations for the treatment of the Prader-Willi phenomenon
WO2023113623A1 (en) * 2021-12-17 2023-06-22 The Cgp Lab Limited Animal, fungal and marine sources of cgp and increased cgp concentration for disease management and for treatment of non-neurological and/or neurological conditions
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
FI941826A7 (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US7202279B1 (en) * 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2003041655A2 (en) 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US7485630B2 (en) 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use

Similar Documents

Publication Publication Date Title
JP2020169171A5 (enExample)
JP2019537599A5 (enExample)
JP2019524883A5 (enExample)
JP2015532295A5 (enExample)
JP2005523922A5 (enExample)
JP2017537940A5 (enExample)
JP2009535307A5 (enExample)
JP2020532547A5 (enExample)
JP2020512337A5 (enExample)
JP2016518437A5 (enExample)
JP2010526146A5 (enExample)
JP2008505157A5 (enExample)
JP2004516314A5 (enExample)
JP2008505117A5 (enExample)
JP2016509047A5 (enExample)
JP2013528180A5 (enExample)
JP2020529994A5 (enExample)
JP2007502295A5 (enExample)
JP2007520452A5 (enExample)
JP2025505200A5 (enExample)
JP2020511536A5 (enExample)
JP2020128426A5 (enExample)
JP2016537432A5 (enExample)
JP2020511450A5 (enExample)
JP2019520344A5 (enExample)